Skip to main content
Clinical Trials/NCT02118025
NCT02118025
Completed
Not Applicable

Prospective Randomized Comparison of Coronary Bypass Grafting With Minimal Extracorporeal Circulation System (MECC) Versus Off-pump Coronary Surgery. New Insights Into Inflammatory Cytokines.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1 site in 1 country230 target enrollmentJanuary 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Enrollment
230
Locations
1
Primary Endpoint
Clinical outcomes
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The investigators aimed to evaluate the clinical results and the inflammatory response of the minimal extracorporeal circulation system (MECC) Compared with off-pump coronary revascularization (OPCABG).

This is a randomized and prospective study in 230 patients with indications for coronary surgery, with 113 patients in the OPCABG group and 117 in the MECC group. The endpoints were the clinical and biochemical results, intra-operative outcomes and the determination of 19 inflammatory circulating markers, 17 of them for the first time analyzed comparing both techniques.

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
June 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Indication for coronary surgery established on the basis of current published guidelines

Exclusion Criteria

  • Documented preoperative systemic proinflammatory status and/or steroid administration within 6 months before surgery.
  • Coexistence of a cardiomyopathy different than coronary artery disease that precise surgical treatment.
  • Left ventricle ejection fraction of 40% or less.
  • Treatment with erythropoietin (EPO) three months before the intervention
  • Hematocrit less than 35% the day prior to the procedure
  • Redo surgery

Outcomes

Primary Outcomes

Clinical outcomes

Time Frame: within the first 30 days (plus or minus 3 days) after surgery

Number of Participants with Adverse Events, e.g, renal failure, atrial fibrillation, acute myocardial infarct, stroke, redo surgery, death.

Secondary Outcomes

  • Determination of increase over the first 48 hours of plasma levels of 19 circulating markers of inflammatory response.(Area Under the Concentration-Time Curve (AUC 0-48 hours))
  • Biochemical outcomes(Within the first 30 days (plus or minus 3 days) after surgery)
  • Operative results(Within the first 30 days (plus or minus 3 days) after surgery)

Study Sites (1)

Loading locations...

Similar Trials